Quantcast

Latest chronic constipation Stories

2012-10-22 22:45:54

Study demonstrates association, not causation, researchers say Patients with chronic constipation may be at increased risk of developing colorectal cancer and benign neoplasms, according to study findings unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas. The study, "Risk of Developing Colorectal Cancer and Benign Neoplasm in Patients with Chronic Constipation," investigated the prevalence and incidence of colorectal cancer...

2010-12-01 14:41:00

NASHVILLE, Tenn., Dec. 1, 2010 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of a patient preference study evaluating Kristalose®( )(lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to liquid lactulose products. The study, which appeared in the Volume 3, 2010 issue of Clinical and Experimental Gastroenterology, showed that patients with chronic constipation preferred...

2010-10-12 01:58:00

GOTHENBURG, Sweden, October 12, 2010 /PRNewswire/ -- Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients. A3309...

2010-04-29 01:59:00

GOTHENBURG, Sweden, April 29, 2010 /PRNewswire/ -- Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held...

2009-11-10 00:30:00

CAMBRIDGE, Mass. and TOKYO, Nov. 10 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand. Linaclotide is currently in Phase 3 clinical development in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and...

2009-05-31 10:45:00

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits -- CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation...

2009-05-12 07:00:00

- Data to be presented at Digestive Disease Week 2009 - CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), during the 2009 Digestive Disease Week...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.